Vol. 20 No. 1 © Oxford University Press, 2005; all rights reserved
The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique
1 Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland, 2 Swiss Centre for International Health, Swiss Tropical Institute, Basel, Switzerland and 3 World Health Organization, Maputo, Mozambique
* Correspondence: Ulla K Griffiths, Department of Vaccines and Biologicals, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. Tel: +41 22 791 42 89, Fax: +41 22 791 42 10; Email:Email: griffithsu{at}who.int
Objective: To estimate the cost-effectiveness of introducing hepatitis B vaccine into routine infant immunization services in Mozambique, which took place in the year 2001.
Methods: A decision analytic model was used to estimate the impact of hepatitis B vaccination. This model was developed for the WHO to estimate the global burden of disease from hepatitis B. Cost data of vaccine delivery and medical treatment related to hepatitis B infection were collected for the analysis.
Findings: The introduction of hepatitis B vaccine has increased the annual budget for immunization services by approximately 56%. It is predicted that more than 4000 future deaths are averted annually by the intervention. In the base case scenario, the incremental costs per undiscounted deaths averted amount to US$436, and the costs per undiscounted DALY averted amount to US$36. Since the major impact of hepatitis B vaccination will not start to be evident for at least another 40 years (deaths from hepatitis B mainly occur between 40–60 years of age), the cost per DALY averted rises to US$47, when using a discount rate of 3% on health effects. We found that the monovalent hepatitis B vaccine was considerably more cost-effective than the hepatitis B vaccine in combination with DTP.
Interpretation: If policy makers value future health benefits equal to current benefits, the cost-effectiveness of infant hepatitis B vaccination is in the range of other primary health care interventions for which similar analysis has been undertaken.
Key Words: hepatitis B, vaccines, modelling, cost-effectiveness, economics, costs, Mozambique
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. HUTTON and F. TEDIOSI THE COSTS OF INTRODUCING A MALARIA VACCINE THROUGH THE EXPANDED PROGRAM ON IMMUNIZATION IN TANZANIA. Am J Trop Med Hyg, August 1, 2006; 75(2_suppl): 119 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. TEDIOSI, G. HUTTON, N. MAIRE, T. A. SMITH, A. ROSS, and M. TANNER PREDICTING THE COST-EFFECTIVENESS OF INTRODUCING A PRE-ERYTHROCYTIC MALARIA VACCINE INTO THE EXPANDED PROGRAM ON IMMUNIZATION IN TANZANIA. Am J Trop Med Hyg, August 1, 2006; 75(2_suppl): 131 - 143. [Abstract] [Full Text] [PDF]
|
|